MBX Biosciences Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 21.21, 131.41, 350.75 ], "ebit_estimate": [ -145.77, -216.19, -252.03, -266.16, -64.59 ], "ebitda_estimate": [ -142.16, -253.31, -287.42, -186.89, -112.13 ], "net_income_estimate": [ -132.56, -201.93, -232.56, -183.48, -87.89 ], "per_share_eps_estimate": [ -2.78, -3.61, -3.92, -2.98, -0.7 ], "eps_nri_estimate": [ -2.81, -3.6, -3.95, -3.06, -1.03 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 18.53, 13.42, 10.56, null, null ], "pretax_income_estimate": [ -137.64, -201.93, -234.3, -182.91, -43.04 ], "operating_cash_flow_per_share_estimate": [ -2.42, -3.19, -3.89, -3, null ], "roa_estimate": [ -39.9, -41.6, null, null, null ], "roe_estimate": [ -18.68, -21.83, -32.59, null, null ], "gross_margin_estimate": [ 80, 83.5, 84.67, 82.33, 83.67 ], "operating_cash_flow_estimate": [ -112.71, -148.58, -181.18, -139.73, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -19.33, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -19.25, "future_eps_nri_estimate_growth": -19.33, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -38.44, "future_ebitda_estimate_growth": -47.52, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -40.5, "future_pretax_income_estimate_growth": -40.28, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -22.14 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -33.23, -38.43, -45.19, -63.37, -50, -55, -58 ], "ebitda_estimate": [ -32.87, -39.11, -42.93, -79.46, null, null, null ], "net_income_estimate": [ -29.89, -35.09, -42.42, -45.8, -48.8, -53.8, -56.8 ], "per_share_eps_estimate": [ -0.63, -0.74, -0.85, -0.81, -0.88, -0.94, -1.03 ], "eps_nri_estimate": [ -0.63, -0.75, -0.86, -0.81, -0.88, -0.94, -1.03 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -30.49, -36.15, -43.88, -45.8, -48.8, -53.8, -56.8 ], "operating_cash_flow_per_share_estimate": [ -0.56, -0.68, -0.67, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ -26.08, -31.67, -31.21, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -19.33, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -19.25, "future_eps_nri_estimate_growth": -19.33, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -38.44, "future_ebitda_estimate_growth": -47.52, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -40.5, "future_pretax_income_estimate_growth": -40.28, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -22.14 }